Antifungal agents. Part I. Amphotericin B preparations and flucytosine

被引：73

作者：

Patel, R ^{[1
]}

机构：

[1] Mayo Clin, Div Infect Dis & Internal Med, Rochester, MN 55905 USA

来源：

MAYO CLINIC PROCEEDINGS | 1998年 / 73卷 / 12期

关键词：

D O I：

10.4065/73.12.1205

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections, Recently, less nephrotic lipid formulations, including amphotericin B lipid complex, amphotericin B cholesteryl sulfate, and liposomal amphotericin B, have been introduced, The pharmacologic properties, main indications, recommended dosages, related costs, and adverse effects of these various preparations are summarized in this review. Orally administered flucytosine is useful in certain infections, particularly cryptococcal meningitis, but it should be used with caution in patients with renal insufficiency.

引用

页码：1205 / 1225

页数：21

共 257 条

[1] A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients [J].

AbeleHorn, M ;

Kopp, A ;

Sternberg, U ;

Ohly, A ;

Dauber, A ;

Russwurm, W ;

Buchinger, W ;

Nagengast, O ;

Emmerling, P .

INFECTION, 1996, 24 (06) :426-432

[2] AMPHOTERICIN-B IN THE TREATMENT OF CANDIDA CHOLECYSTITIS [J].

ADAMSON, PC ;

RINALDI, MG ;

PIZZO, PA ;

WALSH, TJ .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1989, 8 (06) :408-411

[3] Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies [J].

Adedoyin, A ;

Bernardo, JF ;

Swenson, CE ;

Bolsack, LE ;

Horwith, G ;

DeWit, S ;

Kelly, E ;

Klasterksy, J ;

Sculier, JP ;

DeValeriola, D ;

Anaissie, E ;

LopezBerestein, G ;

LlanosCuentas, A ;

Boyle, A ;

Branch, RA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2201-2208

[4] VENTRICULAR ARRHYTHMIAS WITH CONVENTIONAL AND LIPOSOMAL AMPHOTERICIN [J].

AGUADO, JM ;

HIDALGO, M ;

MOYA, I ;

ALCAZAR, JM ;

JIMENEZ, MJ ;

NORIEGA, AR .

LANCET, 1993, 342 (8881) :1239-1239

[5] COMBINED THERAPY WITH FLUCONAZOLE AND FLUCYTOSINE IN MURINE CRYPTOCOCCAL MENINGITIS [J].

ALLENDOERFER, R ;

MARQUIS, AJ ;

RINALDI, MG ;

GRAYBILL, JR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :726-729

[6] POPULATION PHARMACOKINETICS AND RENAL FUNCTION-SPARING EFFECTS OF AMPHOTERICIN-B COLLOIDAL DISPERSION IN PATIENTS RECEIVING BONE-MARROW TRANSPLANTS [J].

AMANTEA, MA ;

BOWDEN, RA ;

FORREST, A ;

WORKING, PK ;

NEWMAN, MS ;

MAMELOK, RD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (09) :2042-2047

[7]

AMPEL NM, 1989, REV INFECT DIS, V11, P897

[8] COMPARISON OF THE INVITRO ANTIFUNGAL ACTIVITY OF FREE AND LIPOSOME-ENCAPSULATED AMPHOTERICIN-B [J].

ANAISSIE, E ;

PAETZNICK, V ;

PROFFITT, R ;

ADLERMOORE, J ;

BODEY, GP .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (08) :665-668

[9] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature [J].

Anaissie, EJ ;

Darouiche, RO ;

AbiSaid, D ;

Uzun, O ;

Mera, J ;

Gentry, LO ;

Williams, T ;

Kontoyiannis, DP ;

Karl, CL ;

Bodey, GP .

CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) :964-972

[10] Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study [J].

Anaissie, EJ ;

Vartivarian, SE ;

AbiSaid, D ;

Uzun, O ;

Pinczowski, H ;

Kontoyiannis, DP ;

Khoury, P ;

Papadakis, K ;

Gardner, A ;

Raad, II ;

Gilbreath, J ;

Bodey, GP .

AMERICAN JOURNAL OF MEDICINE, 1996, 101 (02) :170-176

← 1 2 3 4 5 6 7 8 9 10 →